

DIVI'S LABORATORIES LIMITED

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2009

(Rs.in Lakhs)

		STANDALONE		CONSOLIDATED	
	Particulars	Audited for the year Ended 31.03.2009	Audited for the year Ended 31.03.2008	Audited for the year Ended 31.03.2009	Audited for the year Ended 31.03.2008
	(1)	(4)	(5)	(8)	(9)
1	Net Sales/Income from operations (Net of Excise Duty)	119056	103319	118034	103283
	Other Income	1293	1174	1280	1231
	<u>Total Income:</u>	120349	104493	119314	104514
2	<u>Expenditure:</u>				
	a. (Increase) / Decrease in Stock	(9909)	(3219)	(11847)	(3569)
	b. Consumption of Raw Material	54265	44388	54382	44528
	c. Purchase of Traded Goods			0	0
	d. Staff Cost	6192	5054	6628	5419
	e. Depreciation	4782	3565	4785	3568
	f. Other Expenditure				
	- Manufacturing Expenses	7872	6451	8080	6561
	- Other expenses	11598	8954	12672	9386
	g. Total	74800	65193	74700	65893
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	45549	39300	44614	38621
4	Other Income	1008	187	934	148
5	Profit before Interest & Exceptional Items (3+4)	46557	39487	45548	38769
6	Finance charges	723	1018	725	1019
7	<u>Profit from ordinary activities before Tax (3-4+5+6)</u>	45834	38469	44823	37750
8	Exceptional items	0	0	0	0
9	<u>Profit from ordinary activities before Tax (7+8)</u>	45834	38469	44823	37750
10	Tax Expense				
	- Current Tax	2959	3834	2959	3834
	- MAT Credit Entitlements	(319)	(1930)	(319)	(1930)
	- Deferred Tax	727	1177	497	1054
	- Fringe Benefit Tax	22	32	22	32
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	42445	35356	41664	34760

12	Extra-ordinary items (net of tax expense)	0	0		0
13	Net Profit (+)/Loss(-) for the period (11-12)	42445	35356	41664	34760
14	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	1295	1291	1295	1291
15	Reserves excluding revaluation reserves	124884	86107	122843	84849
16	Earnings per Share:				
a)	Basic Earnings Per Share before extra-ordinary items Rs.	65.59	54.77	64.38	53.84
	Diluted Earnings Per Share before extra-ordinary items Rs.	64.92	54.14	63.73	53.23
b)	Basic Earnings Per Share after extra-ordinary items Rs.	65.59	54.77	64.38	53.84
	Diluted Earnings Per Share after extra-ordinary items Rs.	64.92	54.14	63.73	53.23
17	Aggregate of non-promoter shareholding - No. of shares - Percentage of shareholding	30173725 46.59%	29992100 46.46%	30173725 46.59%	29992100 46.46%
18	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered No. of shares % of shares	Nil 34584300 53.41%	Nil 34565000 53.54%	Nil 34584300 53.41%	Nil 34565000 53.54%

NOTES:

1. The above results for the year ended 31st March 2009, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 6th June, 2009.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard - 17 notified under the Companies Act, 1956.
3. The consolidated results include the audited results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG
4. Other Expenses include an amount of Rs.4553 lakhs towards loss on forex fluctuations and forward hedging/swap arrangements and an amount of Rs.490 lakhs towards employee compensation expense on Employee stock options.
5. The company has not exercised the option available under Clause No.46 of Accounting Standard -11 notified under the Companies Accounting Standard (Amendment) Rules, 2009 for capitalizing or deferring exchange differences on long term monetary items.
6. The company made provision for income-tax in respect of its profits from SEZ Unit considering 100% exemption on profits derived from exports as against the prevailing interpretation of Section 10AA(7) of the Income-tax Act, 1961 for exemption of export profits of the SEZ Unit as a proportion of the export turnover of the SEZ Unit to the total turnover of the company as a whole. Had the prevailing provision of Section 10AA(7) and its current interpretation been followed, the provision for the current income-tax will be higher by Rs.3425 lakhs and the profit after tax (PAT) for the year will be lower to that extent.

7. The Board of Directors of the company has recommended a dividend of Rs.6 per equity share of Rs.2 each (i.e., 300%), subject to approval of members.
8. The Board has also recommended issue of bonus shares in the ratio of one share for every share held, subject to approval of members.
9. The figures for the previous year/period have been regrouped or recasted, wherever necessary.
10. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.03.2009:
Opening: Nil, Received during the Quarter: 54, Resolved: 54, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 6th June, 2009

Dr.Murali K.Divi
Chairman & Managing Director